Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,573.45
(
-0.11%
)
US TECH 100
23,436.80
(
-0.35%
)
Dow Jones
46,255.77
(
0.10%
)
Brent Oil
99.97
(
3.28%
)
Bitcoin
69,543.00
(
-1.91%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mouton29 post# 7087

Saturday, 01/19/2008 12:06:40 AM

Saturday, January 19, 2008 12:06:40 AM

Post# of 19309
>as to the short duration, the protocol in the published study is 4 days of infusion and the Leo study is 5 days -- is one extra day likely to be that important?<

Probably not. What is more consequential than the number of days of treatment is whether a trial’s protocol allows for antithrombin dose adjustment based on a patient’s antithrombin level during treatment. Leo’s trial presumably permits such adjustment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today